Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer
Status:
Withdrawn
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Preclinical data has demonstrated that entinostat (SNDX-275) can enhance fulvestrant
sensitivity in hormone receptor-positive breast cancer in animal models. The addition of
entinostat to fulvestrant will provide clinical benefit to patients with locally advanced or
metastatic breast when compared to fulvestrant plus placebo. Also, based on previous data,
patients exposed to entinostat who demonstrate an elevated level of protein lysine
acetylation will have an improved efficacy outcome.